HC Wainwright & Co. Reiterates Buy Rating on TG Therapeutics, Inc. (TGTX)

Market Context

TG Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $55.01 with a market capitalization of $5.1B. The stock has gained 47.1% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for TG Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for TG Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 1 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jul 13, 2026	HC Wainwright & Co.	Buy	N/A
Jul 07, 2026	B of A Securities	Underperform	N/A
Jul 06, 2026	HC Wainwright & Co.	Buy	N/A
May 27, 2026	HC Wainwright & Co.	Buy	N/A
May 06, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TGTX Stock Page